Effects of aging on dehydroepiandrosterone sulfate in relation to fasting insulin levels and body composition assessed by bioimpedance analysis

Metabolism: Clinical and Experimental

Volumn 46, Issue 7, 1997, Pages 826-832

  Denti, Licia ^a   Pasolini, Giuseppe ^a   Sanfelici, Laura ^a   Ablondi, Fabrizio ^a   Freddi, Marilena ^a   Benedetti, Raffaella ^a   Valenti, Giorgio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE SULFATE;

ADULT; AGING; ANALYTIC METHOD; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; DIET RESTRICTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0030790089     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90130-X     Document Type: Article

References (60)

1. Baulieu EE, Corpechot C, Dray F, et al: An adrenal-secreted "androgen": Dehydroepiandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroids conjugated in man. Recent Prog Horm Res 21:411-500, 1965
2. Cleary MP, Seidenstat R, Tannen RH, et al: The effect of dehydroepiandrosterone on adipose tissue cellularity in mice. Proc Soc Exp Biol Med 171:276-284, 1982
3. Yen TT, Allan JA, Pearson DV, et al: Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 12:409-413, 1977
4. Coleman DL: Antiobesity effects of etiocholanolones in diabetes (db), viable yellow (Avy) and normal mice. Endocrinology 117:2279-2283, 1985
5. Coleman DL, Schwizer RW, Leiter EH: Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 33:26-32, 1984
6. Tagliaferro AR, Davis JR, Truchon S, et al: Effects of dehydroepiandrosterone acetate on metabolism, body weight and composition of male and female rats. J Nutr 116:1977-1983, 1986
7. Coleman DL, Leiter EH, Applezweig N: Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C57BL/ KsJ-db/db). Endocrinology 115:239-243, 1984
8. Ben-David M, Dikstein S, Bismuth G, et al: Antihypercholesterolemic effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 125:1136-1140, 1967
9. Gordon GB, Bush DE, Weisman HF: Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimai injury. J Clin Invest 712-720, 1988
10. Zumoff B, Troxler RG, O'Connor J, et al: Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis 2:58-67, 1982
11. Barrett-Connor E, Khaw KT, Yen SSC: A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 315:1519-1524, 1986
12. Barrett-Connor E, Khaw KT: Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 317:711, 1987 (letter)
13. Coleman MP, Key TJ, Wang DY, et al: A prospective study of obesity, lipids, apolipoproteins and ischemic heart disease in women. Atherosclerosis 92:177-185, 1992
14. Shwartz AG: Inhibition of spontaneous breast cancer formation in female C3H (Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 39:1129-1132, 1979
15. Nyce JW, Magee PN, Hard GC, et al: Inhibition of 1,2 dimethylhydrazine induced colon tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis 5:57-62, 1984
16. Lucas JA, Ahmed SA, Casey LM, et al: Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroepiandrosterone. J Clin Invest 75:2091-2093, 1985
17. Tannen RH, Schwartz AG: Reduced weight gain and delay of Coombs positive hemolytic anemia in NZB mice treated with dehydroepiandrosterone (DHEA). Fed Proc 42:463-466, 1982
18. Wang DY, Hayward JL, Bulbrook RD, et al: Plasma dehydroepiandrosterone and androstenedione sulfates, androstenedione and urinary androgen metabilites in normal British and Japanese women. Eur J Cancer 12:951-958, 1976
19. Vermeulen A: Adrenal androgens and aging, in Gennazzani AR, Thijssen JHH, Siiteri PK (eds): Adrenal Androgens. New York, NY, Raven, 1980, pp 207-217
20. Meldrum DR, Davidson BJ, Tataryn IV, et al: Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 57:624-628, 1981
21. Khaw KT, Tazuke S, Barrett-Connor E: Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med 18:1705-1709, 1982
22. Orentreich N, Brind JL, Rizer L, et al: Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59:551-555, 1984
23. Rudman D, Shetty KR, Mattson DE: Plasma dehydroepiandrosterone sulfate in nursing home men. J Am Geriatr Soc 38:421-427, 1990
24. Salvini S, Stampfer MJ, Barbieri RL, et al: Effects of age, smoking and vitamins on plasma DHEAS levels: A cross-sectional study in men. J Clin Endocrinol Metab 74:139-143, 1992
25. Orentreich N, Brind JL, Vogelman JH, et al: Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75:1002-1004, 1992
26. Birkenhager-Gillese EG, Derksen J, Lagaay AM: Dehydroepiandrosterone sulfate (DHEAS) in the oldest old, aged 85 and over. Ann NY Acad Sci 719:543-552, 1994
27. Odell WD, Parker LN: Control of adrenal androgen production. Endocr Res 10:617-630, 1985
28. Liu CH, Laughlin GA, Fischer UG, et al: Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: Evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 71:900-906, 1990
29. Nestler JE, Usiskin KS, Barlascini CO, et al: Suppression of serum dehydroepiandrosterone sulfate levels by insulin. An evaluation of possible mechanisms. J Clin Endocrinol Metab 69:1040-1046, 1989
30. Nestler JE, McLanahan MA, Clore JN, et al: Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Metab 74:362-367, 1992
31. Lopez SA, Krehl WA: A possible interrelation between glucose-6-phosphate dehydrogenase and dehydroepiandrosterone in obesity. Lancet 2:485-487, 1967
32. De Pergola G, Giagulli VA, Garruti G, et al: Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. Metabolism 40:187-190, 1991
33. Nafziger AN, Herrington DM, Bush TL: Dehydroepiandrosterone and dehydroepiandrosterone sulfate: Their relation to cardiovascular disease. Epidemiol Rev 13:267-293, 1991
34. Nowaczynski W, Fragachas F, Silah J: Further evidence of altered adrenocortical functions in hypertension: Dehydroepiandrosterone secretion rate. Can J Biochem 46:1031-1038, 1968
35. Barrett-Connor E: Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 117:807-811, 1992
36. Beer NA, Jakubowicz DJ, Beer RM: Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76:178-183, 1993
37. Beer NA, Jakubowicz DJ, Beer RM, et al: The calcium channel blocker amlodipine raises serum dehydroepiandrosterone-sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76:1464-1469, 1993
38. Beer NA, Jakubowicz DJ, Beer RM: Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. J Clin Endocrinol Metab 79:1077-1081, 1994
39. Nestler JE, Beer NA, Jakubowicz DJ: Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab 80:700-706, 1995
40. Durnin J, Womersley J: Body fat assessed fom total body density and its estimation from skinfold thicknesses: Measurements on 481 men and women aged 16 to 72 years. Br J Nutr 32:77-97, 1974
41. Siri WB: Gross composition of the body, in Tobias CA, Laurence JH (eds): Advances in Biological and Medical Physics, vol 4. New York, NY, Academic, 1956, pp 239-280
42. Segal KR, Van Loan MD, Fitzgerald PI, et al: Lean body mass estimation by bioelectrical impedance analysis: A four site cross-validation study. Am J Clin Nutr 47:7-14, 1988
43. Deurenberg P, Van der Kooij K, Evers P, et al: Assessment of body composition by bioelectric impedance in a population aged >60 years. Am J Clin Nutr 51:3-6, 1990
44. Haffner SM, Valedz RA, Mykkanen L, et al: Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 43:599-603, 1994
45. Chumlea WC, Baumgartner RN, Vellas BP: Anthropometry and body composition in the perspective of nutritional status in the elderly. Nutrition 7:57-60, 1991
46. Nestler JE, Barlascini CO, Clore JN, et al: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal man. J Clin Endocrinol Metab 66:57-61, 1988
47. Usiskin KS, Butterworth S, Clore JN: Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 14:457-463, 1990
48. Welle S, Jozefowicz R, Staat M: Failure of DHEA to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 71:1259-1264, 1990
49. Morales AJ, Nolan JJ, Nelson JC, et al: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 6:1360-1367, 1994
50. Mortola JF, Yen SSC: The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 71:696-704, 1990
51. Williams DP, Boyden TW, Pamenter RW: Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. J Clin Endocrinol Metab 77:80-85, 1993
52. Barrett-Connor E, Ferrara A: Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio and noninsulin-dependent diabetes in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metab 81:59-64, 1996
53. Ferland M, Despres JP, Tremblay A, et al: Assessment of adipose tissue distribution by computed axial tomography in obese women: Association with body density and anthropometric measurements. Br J Nutr 61:139-148, 1989
54. Pouliot MC, Despres JP, Lemieux S: Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73:460-468, 1994
55. Hauner H, Bognar E, Blum A: Body fat distribution and its association with metabolic and hormonal risk factors in women with angiographically assessed coronary artery disease. Evidence for the presence of a metabolic syndrome. Atherosclerosis 105:209-216, 1994
56. Cumming DC, Rebar RW, Hopper BR, et al: Evidence for an influence of the ovary on circulating dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 54:1069-1071, 1982
57. Lucky AW, Marynick SP, Rebar RW, et al: Replacement oral ethynylestradiol therapy for gonadal dysgenesis: Growth and adrenal androgen studies. Acta Endocrinol (Copenh) 91:519-524, 1979
58. Lobo RA, March CM, Goebelsmann O, et al: The modulating role of obesity and 17 beta-estradiol (E2) on bound and unbound E2 and adrenal androgens in oophorectomized women. J Clin Endocrinol Metab 54:320-324, 1982
59. Baumgartner RN, Chumlea WC, Roche AF: Bioelectric impedance phase angle and body composition. Am J Clin Nutr 48:16-23, 1988
60. Friedman AJ, Ravnikar VA, Barbieri RL: Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril 47:398-401, 1987